60 Degrees Pharmaceuticals: Advancing FDA-Approved Malaria Drug & Targeting $245M Babesiosis Market
Nov. 7, 2025
60 Degrees Pharmaceuticals (NASDAQ: SXTP) is a growth-stage biotech company developing novel treatments for vector-borne diseases. In this exclusive investor overview, CEO Geoff Dow discusses how the company’s FDA-approved malaria prevention drug ARAKODA® (tafenoquine) is driving commercial progress — and how its next major focus, babesiosis, represents a transformative market opportunity in the U.S.
Key Highlights:
• FDA-Approved Product: ARAKODA® offers once-weekly malaria prevention with a strong safety profile and global applicability.
• Expanding Indications: Clinical program advancing tafenoquine for babesiosis, a tick-borne disease with no FDA-approved treatment.
• Strong Early Data: First patient in the relapsing babesiosis study tested negative for infection (October 2025).
• Regulatory Momentum: Breakthrough Therapy Designation request submitted; FDA Type B meeting planned for early 2026.
• Market Potential: Estimated 380,000 addressable U.S. patients annually, representing ~$245M in potential peak annual sales and ~$1.1B cumulative revenue opportunity through 2035.
• Experienced Leadership: Proven team with multiple product approvals and commercial launches.
Why It Matters to Investors:
• 60 Degrees is capitalizing on established infrastructure and a clinically validated compound to expand into high-growth infectious disease markets with significant unmet needs.
60 Degrees Pharmaceuticals is a client of RedChip. To learn more about SXTP and to read our full disclosure, visit: SXTPinfo.com.
